> 首页 > 产品 > 一抗 > 其他 > Anti-ANG2 & VEGFA Reference Antibody (Vanucizumab)

Anti-ANG2 & VEGFA Reference Antibody (Vanucizumab)

Anti-ANG2 & VEGFA Reference Antibody (Vanucizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 96%.
The purity of Anti-ANG2 & VEGFA Reference Antibody (Vanucizumab) is more than 95%, determined by SEC-HPLC.
Vanucizumab bound to ANG2 protein, and then rebounded to secondary antibodies (Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Vanucizumab bound to in huANG2-His, and the EC50 was 0.288 nM.
Vanucizumab bound to VEGFA protein, and then rebounded to secondary antibodies (Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Vanucizumab bound to in huVEGFA-His, and the EC50 was 0.009 nM.
Co-incubation of Vanucizumab with VEGF protein, then with the addition of VEGF-NF-AT-HEK293 cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Vanucizumab can neutralize VEGF-165, and the IC50 was 1.075 nM.
The detected molecular weight of Anti-ANG2 & VEGFA Reference Antibody (Vanucizumab) is 146.62 kDa.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q9UID3 & P15692
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-like

Additional Information
Target/Specificity	VEGFA,ANGPT2
Expression system	CHO

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.